Pyridoxal 5 phosphate for neuroleptic-induced tardive dyskinesia

Cochrane Database of Systematic Reviews

Volumn 2015, Issue 4, 2015, Pages

  Adelufosi, Adegoke Oloruntoba ^a   Abayomi, Olukayode ^b   Ojo, Tunde Massey Ferguson ^c  

^a Northern Regional Health Authority   (Canada)

^b Ladoke Akintola University Teaching Hospital   (Nigeria)

^c Clinicial Sciences   (Nigeria)

Author keywords

[No Author keywords available]

Indexed keywords

NEUROLEPTIC AGENT; PLACEBO; PYRIDOXAL 5 PHOSPHATE; VITAMIN B COMPLEX;

DETERIORATION; DRUG EFFECT; DRUG EFFICACY; DRUG WITHDRAWAL; HUMAN; MENTAL DISEASE; PRIORITY JOURNAL; PSYCHOSIS; REVIEW; SCHIZOPHRENIA; SINGLE DRUG DOSE; SYSTEMATIC REVIEW; TARDIVE DYSKINESIA; TREATMENT OUTCOME; ADULT; AGED; DYSKINESIA, DRUG-INDUCED; FEMALE; MALE; META ANALYSIS; MIDDLE AGED; RANDOMIZED CONTROLLED TRIAL (TOPIC);

ADULT; AGED; ANTIPSYCHOTIC AGENTS; DYSKINESIA, DRUG-INDUCED; FEMALE; HUMANS; MALE; MIDDLE AGED; PYRIDOXAL PHOSPHATE; RANDOMIZED CONTROLLED TRIALS AS TOPIC; SCHIZOPHRENIA; VITAMIN B COMPLEX;

EID: 84944474513     PISSN: 14651858     EISSN: None     Source Type: Journal    
DOI: 10.1002/14651858.CD010501.pub2     Document Type: Review

References (58)

1. Lerner V, Miodownik C, Kaptsan A, Cohen H, Matar M, Loewenthal U, et al. Vitamin B6 in the treatment of tardive dyskinesia: a double-blind, placebo-controlled, crossover study. American Journal of Psychiatry 2001;158(9):1511-4.
2. Lerner V, Miodownik C, Kapstan A, Bersudsky Y, Libov I, Sela B-M, et al. Vitamin B6 treatment for tardive dyskinesia: a randomized, double-blind, placebo-controlled, crossover study. Journal of Clinical Psychiatry 2007;68(11):1648-54.
3. Miodownik C, Cohen H, Kotler M, Lerner V. Vitamin B6 ad-on therapy in treatment of schizophrenic patients with psychotic symptoms and movement disorders. Harefuah 2003;142(8-9):592-6, 647.
4. Greenberg WM. A 12-week, double-blind, augmentation study of the effects of folic acid, B-12, and pyridoxine in lowering homocysteine levels and treating psychopathology and cognitive deficits in schizophrenia. Stanley Foundation Research Programs 2003.
5. Lerner V, Miodownik C, Kaptsan A, Cohen H, Loewental U, Kotler M. Double-blind evaluation of Vitamin B6 vs Placebo in treatment of tardive dyskinesia. European Neuropsychopharmacology. 1999; Vol. 9:S369.
6. Lerner V, Cohen H. A double-blind, randomised, placebo-controlled, crossover study of the effects of vitamin B6 in 50 in-patients with tardive dyskinesia. Stanley Foundation Research Institute 2002.
7. Lerner V. Vitamin B-sub-6. The experience in treating psychotic symptoms and psychotropic drug-indced movement disorders. In: Pletson JE editor(s). Psychology and Schizophrenia. Hauppauge, NY, US: Nova Science Publishers, 2007:105-38.
8. Lerner V. Vitamin B6 for tardive movement disorder. Stanley Foundation Research Programs 2009.
9. NCT00202280. Efficacy of treating first episode psychosis with folic acid, vitamin B12 and B6 in addition to antipsychotic medication. http://www.clinicaltrials.gov./ct2/show/NCT00202280?term=NCT00202280&rank=1.
10. Venegas F, Sinning O, Millan A, Miranda C, Robles G, Astudillo A, et al. Pyridoxine for drug induced dyskinesia. A placebo- controlled randomised cross-over trial [Piridoxina en el manejo de Disquinesias Tardías. Un estudio placebo controlado, randomizado, doble ciego y cruzado]. Revista Chilena de Neuropsiquiatrica 2006;44(1):9-14.
11. Xiao G, Jin Y, Luo X. The effect of huangqi injection in the treatment of tardive neuropathy caused by acute organophosphorus insecticide poisoning. Herald of Medicine 2002;21(9):558-60.
12. NCT00917293. Safety and efficacy of avastrem (pyridoxal 5' -phosphate) in the treatment of tardive dyskinesia. http://www.clinicaltrials.gov 2009.
13. Adler LA, Edson R, Lavori P, Peselow E, Duncan E, Rosenthal M, et al. Long-term treatment effects of vitamin E for tardive dyskinesia. Biological Psychiatry 1998;43:868-72.
14. Altman DG, Bland JM. Detecting skewness from summary information. BMJ 1996;313:1200.
15. American Psychiatric Association. Tardive dyskinesia: a task force report of the American Psychiatric Association. Washington DC 1992.
16. Ascher-Svanum H, Zhu B, Faries D, Peng X, Kinon BJ, Tohen M. Tardive dyskinesia and the 3-year course of schizophrenia: results from a large, prospective, naturalistic study. Journal of Clinical Psychiatry 2008;69(10):1580-8.
17. Ayehu M, Shibre T, Milkias B, Fekadu A. Movement disorders in neuroleptic-naïve patients with schizophrenia spectrum disorders. BMC Psychiatry 2014;14:280.
18. Barnes TRE, Edwards JG. The side-effects of antipsychotic drugs. In: Barnes TRE editor(s). Antipsychotic Drugs and their Side-effects. CNS and Neuromuscular Effects. Vol. I, London: Harcourt Brace & Company, 1993.
19. Bassitt DP, Louzã Neto MR. Clozapine efficacy in tardive dyskinesia in schizophrenic patients. European Archives Psychiatry and Clinical Neuroscience 1998;248(4):209-11.
20. Boissel JP, Cucherat M, Li W, Chatellier G, Gueyffier F, Buyse M, et al. The problem of therapeutic efficacy indices. 3. Comparison of the indices and their use [Apercu sur la problematique des indices d'efficacite therapeutique, 3: comparaison des indices et utilisation. Groupe d'Etude des Indices D'efficacite]. Therapie 1999;54(4):405-11. [PUBMED: 10667106]
21. Browne S, Roe M, Lane A, Gervin M, Morris M, Kinsella A, et al. Quality of life in schizophrenia: relationship to sociodemographic factors, symptomatology and tardive dyskinesia. Acta Psychiatrica Scandinavica 1996;94:118-24.
22. CaroffSN, Campbell EC, Havey J, Sullivan KA, Mann SC, Gallop R. Treatment of tardive dyskinesia with donepezil: A pilot study. Journal of Clinical Psychiatry 2001;62(10):772-5.
23. Casey DE. Neuroleptic-induced extrapyramidal syndromes and tardive dyskinesia. In: Hirsch S, Weinberger DR editor(s). Schizophrenia. Oxford: Blackwell, 1995:546-65.
24. Chakos MH, Alvir JMJ, Woerner MG, Koreen A, Geisler S, MayerhoffD, et al. Incidence and correlates of tardive dyskinesia in first episode of schizophrenia. Archives of General Psychiatry 1996;53:313-9.
25. Chouinard G, Margolese HC. Manual for the Extrapyramidal Symptom Rating Scale (ESRS). Schizophrenia Research 2005;76(2-3):247-65.
26. Correll CU, Schenk EM. Tardive dyskinesia and new antipsychotics. Current Opinion in Psychiatry 2008;21(12):151-6.
27. Deeks J. Issues in the selection for meta-analyses of binary data. Proceedings of the 8th International Cochrane Colloquium; 2000 Oct 25-28; Cape Town. Cape Town: The Cochrane Collaboration, 2000.
28. Elbourne DR, Altman DG, Higgins JP, Curtin F, Worthington HV, Vail A. Meta-analyses involving cross-over trials: methodological issues. International Journal of Epidemiology 2002;31(1):140-9.
29. Fay-McCarthy M, Kendrick KA, Rosse RB, Schwartz BL, Peace T, Wyatt RJ, et al. The effect of nifedipine on tardive dyskinesia: a double blind study in eighteen patients. Schizophrenia Research 1997;24(1-2):271.
30. Fenton WS. Prevalence of spontaneous dyskinesia in schizophrenia. Journal of Clinical Psychiatry 2000;61(Suppl 4):10-4.
31. Fleiss JL. The crossover study. The design and analysis of clinical experiments. Chichester: John Wiley & Sons 1984.
32. Higgins JP, Thompson SG, Deeks JJ, Altman DG. Measuring inconsistency in meta-analyses. BMJ 2003;327:557-60.
33. Higgins JPT, Green S (editors). Cochrane Handbook for Systematic Reviews of Interventions Version 5.0.2 [updated September 2011]. The Cochrane Collaboration, 2011. Available from www.cochrane-handbook.org.
34. Hoenders R, Bartels-Velthuis A, Vollbehr N, Bruggeman R, Knechtering R, de Jong J. Natural medicines in schizophrenia: A systematic review. Journal of Alternative and Complementary Medicine. 2014; Vol. 20, issue 5:A79-80.
35. Hutton JL. Number needed to treat and number needed to harm are not the best way to report and assess the results of randomised clinical trials. British Journal of Haematology 2009;146(1):27-30.
36. Kane J, Woerner M, Borenstein M. Integrating incidence and prevalence of tardive dyskinesia. Psychopharmacology Bulletin 1986;22:254-8.
37. Kay SR, Fiszbein A, Opler LA. The positive and negative syndrome scale (PANSS) forschizophrenia. Schizophrenia Bulletin 1987;13:261-76.
38. Leung SK, Ungvari GS, Ng FS, Cheung HK, Leung T. Tardive dyskinesia in Chinese inpatients with chronic schizophrenia. Progress in Neuropharmacology and Biological Psychiatry 2003;27(6):1029-35.
39. Lopez-Munoz, Alamo C, Cuenca E, Shen WW, Clervoy P, Rubio G. History of the discovery and clinical introduction of chlorpromazine. Annals of Clinical Psychiatry 2005;17(3):113-35.
40. Marshall M, Lockwood A, Bradley C, Adams C, Joy C, Fenton M. Unpublished rating scales: a major source of bias in randomised controlled trials of treatments for schizophrenia. British Journal of Psychiatry 2000;176:249-52.
41. McGrath J, Soares-Weiser K. Vitamin E for neuroleptic-induced tardive dyskinesia. Cochrane Database of Systematic Reviews 2001, Issue 4. [DOI: 10.1002/14651858.CD000209]
42. Miodownik C, Meoded A, Libov I, Bersudsky Y, Sela B, Lerner V. Pyridoxal plasma level in schizophrenic and schizoaffective patients with and without tardive dyskinesia. Clinical Neuropharmacology 2008;31:197-203.
43. Moher D, Schulz KF, Altman D, CONSORT Group (Consolidated Standards of Reporting Trials). The CONSORT statement: revised recommendations for improving the quality of reports of parallel-group randomized trials. JAMA 2001;285:1987-91.
44. Nasrallah HA. Focus on lower risk of tardive dyskinesia with atypical antipsychotics. Annals of Clinical Psychiatry 2006;18(1):57-62.
45. Nelson, LA, McGuire JM, Hausafus SN. Melatonin for the treatment of tardive dyskinesia. Annals of Pharmacotherapy 2003;37:1128-31.
46. Niehaus DJH, Du Plessis SA, Koen L, Lategan BH, SteynJ, Oosthuizen PP, et al. Predictors of abnormal involuntary movement in an African schizophrenia population. Journal of Neuropsychiatry and Clinical Neurosciences 2008;20:317-26.
47. Sachdev PS. Depression-dependent exacerbation of tardive dyskinesia. British Journal of Psychiatry 1989;155:253-5.
48. Schaumburg H, Kaplan WA, Vick N, Rasmus S, Pleasure D, Brown MJ. Sensory neuropathy from pyridoxine abuse - A new megavitamin syndrome. New England Journal of Medicine 1983;309:445-8.
49. Schünemann HJ, Oxman AD, Vist GE, Higgins JPT, Deeks JJ, Glasziou P, et al. Chapter 12: Interpreting results and drawing conclusions. In: Higgins JPT, Green S editor(s). Cochrane Handbook for Systematic Reviews of Interventions. The Cochrane Collaboration, 2008:359-83.
50. Soares-Weiser K, Rathbone J. Calcium channel blockers for neuroleptic-induced tardive dyskinesia. Cochrane Database of Systematic Reviews 2004, Issue 1. [DOI: 10.1002/14651858.CD000206.pub2]
51. Tammenmaa I, McGrath J, Sailas EES, Soares-Weiser K. Cholinergic medication for neuroleptic-induced tardive dyskinesia. Cochrane Database of Systematic Reviews 2002, Issue 3. [DOI: 10.1002/14651858.CD000207]
52. Tenback DE, van Harten PN, SlooffCJ, van Os J, SOHO Study Group. Worsening of psychosis in schizophrenia is longitudinally associated with tardive dyskinesia in the European Schizophrenia Outpatient Health Outcomes study. Comprehensive Psychiatry 2007;48(5):436-40.
53. Teo JT, Edwards MJ, Bhatia K. Tardive dyskinesia is caused by maladaptive synaptic plasticity: a hypothesis. Movement Disorders 2012;27:1205-15.
54. Waddington JL, Youssef HA, Dolphin C, Kinsella A. Cognitive dysfunction, negative symptoms, and tardive dyskinesia in schizophrenia. Their association in relation to topography of involuntary movements and criterion of their abnormality. Archives of General Psychiatry 1987;44(10):907-12.
55. Woerner MG, Saltz BL, Kane JM, Lieberman JA, Alvir JMJ. Diabetes and development of tardive dyskinesia. American Journal of Psychiatry 1993;150:966-8.
56. Xia J, Adams CE, Bhagat N, Bhagat V, Bhoopathi P, El-Sayeh H, et al. Loss to outcomes stakeholder survey: the LOSS study. Psychiatric Bulletin 2009;33(7):254-7.
57. Yassa R, Jeste DV. Gender differences in tardive dyskinesia: a critical review of the literature. Schizophrenia Bulletin 1992;18:701-15.
58. Zhang XY, Zhou DF, Cao LY, Xu CQ, Chen DC, Wu GY. The effect of vitamin E treatment on tardive dyskinesia and blood superoxide dismutase: a double-blind placebo-controlled trial. Journal of Clinical Psychopharmacology 2004;24:83-6.